<DOC>
	<DOCNO>NCT02022033</DOCNO>
	<brief_summary>The investigator preliminary data suggest FOLFOX-A may equal superior activity compare FOLFIRINOX appear well tolerate . Therefore , FOLFOX-A may better regimen adjuvant set patient resect pancreatic cancer . This protocol obtain preliminary data safety disease-free overall survival follow administration FOLFOX-A patient resect pancreatic cancer .</brief_summary>
	<brief_title>BrUOG 295 : Adjuvant FOLFOX-A For Resected Pancreatic Cancer : A Phase II Brown University Oncology Research Group Trial</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologic proof primary pancreas invasive adenocarcinoma adenosquamous cancer , manage potentially curative resection ( i.e. , removal gross tumor ) . Patients invasive adenocarcinoma also contain component intraductal papillary mucinous neoplasm ( IPMN ) eligible . Interval definitive tumorrelated surgery registration 2170 day . Patients stag accord 6th edition AJCC stag system pathologic stage T13 , N01 , M0 eligible . Post resection serum CA199 ≤ 180 units/mL within 21 day registration study . Preexisting neuropathy &lt; grade 1 ( per CTCAE ) . ECOG performance status 0 1 . Age ≥ 18 Not pregnant nursing . Women child bear potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 7 day prior begin treatment . Postmenopausal woman ( surgical menopause lack menses &gt; 12 month ) need pregnancy test , please document status . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment . Required Initial Laboratory Values : Neutrophils ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min Total bilirubin ≤ 1.5 x ULN AST ( SGOT ) &amp; ALT ( SGPT ) ≤ 2.5 x ULN Alkaline phosphatases &lt; 2.5x ULN Abdominal CT scan contrast chest CT/xray ( CT chest prefer ) within 6 week registration study . Patients PET/MRI chest/abdomen instead . Patients serious medical risk factor involve major organ system investigator considers unsafe patient receive FOLFOXA Prior hypersensitivity Oxaliplatin Abraxane investigator opinion would put patient risk reexposed Patients islet cell ( neuroendocrine ) tumor , cystadenomas , cystadenocarcinomas , carcinoid tumor , duodenal carcinoma , distal bile duct , ampullary carcinoma . Prior systemic chemotherapy pancreas cancer ; note prior chemotherapy different cancer allowable . Patients must receive chemotherapy year prior register study No prior invasive malignancy within prior two year . However , patient early stage malignancy expect require treatment next 2 year ( early stage , resect breast cancer asymptomatic prostate cancer ) eligible . This must document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Resected</keyword>
	<keyword>Invasive adenocarcinoma</keyword>
	<keyword>adenosquamous cancer</keyword>
	<keyword>Intraductal papillary mucinous neoplasm</keyword>
</DOC>